AARD.US Aardvark Therapeutics, Inc. Common Stock

Healthcare Pharmaceuticals USA Stocks
1.52 USD
Close of Nov 13, 2026
0.9300 16.60
Market cap
USD 33.3M
P/E
-
P/B
0.47x
ROE
-96.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is AARD.US undervalued?

Graham number

The Graham number of Aardvark Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aardvark Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Aardvark Therapeutics, Inc. Common Stock yet.

Aardvark Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Full company profile